[{"indications": "Indications\u00a0focal and secondary generalised tonic-clonic\r\nseizures, primary generalised tonic-clonic seizures; trigeminal neuralgia;\r\nprophylaxis of bipolar disorder unresponsive to lithium; adjunct in\r\nacute alcohol withdrawal [unlicensed] (section 4.10.1); diabetic neuropathy [unlicensed]\r\n(section 6.1.5)", "name": "CARBAMAZEPINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.8 Antiepileptic drugs", "4.8.1 Control of the epilepsies", "Carbamazepine and related antiepileptics", "CARBAMAZEPINE"], "cautions": "Cautions\u00a0cardiac disease (see also\r\nContra-indications); skin reactions (see\r\nalso Blood, Hepatic, or Skin Disorders, below and under Side-effects); test for\r\nHLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid\r\nunless no alternative\u2014risk of Stevens-Johnson syndrome in presence\r\nof HLA-B*1502 allele); history of haematological reactions\r\nto other drugs; manufacturer recommends\r\nblood counts and hepatic and renal function tests (but evidence of\r\npractical value uncertain); may exacerbate\r\nabsence and myoclonic seizures; consider\r\nvitamin D supplementation in patients who are immobilised for long\r\nperiods or who have inadequate sun exposure or dietary intake of calcium; susceptibility to angle-closure glaucoma; cross-sensitivity reported with oxcarbazepine and with phenytoin\r\n(see also Antiepileptic Hypersensitivity\r\nSyndrome); avoid abrupt withdrawal; interactions: see Interactions in section 4.8.1 and Appendix 1 (carbamazepine)Blood, hepatic, or skin disorders\u00a0Patients or their carers should be told how to recognise signs of\r\nblood, liver, or skin disorders, and advised to seek immediate medical\r\nattention if symptoms such as fever, rash, mouth ulcers, bruising,\r\nor bleeding develop. Carbamazepine should be withdrawn\r\nimmediately in cases of aggravated liver dysfunction or acute liver\r\ndisease. Leucopenia that is severe, progressive, or associated\r\nwith clinical symptoms requires withdrawal (if necessary under cover\r\nof a suitable alternative).", "side-effects": "Side-effects\u00a0\n(From Carbamazepine and related antiepileptics: British National Formulary)\nCarbamazepine and related antiepileptics; also dry\r\nmouth, nausea, vomiting, oedema, ataxia, dizziness, drowsiness, fatigue,\r\nheadache, hyponatraemia (leading in rare cases to water intoxication),\r\nblood disorders (including eosinophilia, leucopenia, thrombocytopenia,\r\nhaemolytic anaemia, and aplastic anaemia), dermatitis, urticaria; less commonly diarrhoea, constipation, involuntary movements\r\n(including nystagmus), visual disturbances; rarely abdominal pain, anorexia, hepatitis, jaundice, vanishing bile duct\r\nsyndrome, cardiac conduction disorders, hypertension, hypotension,\r\nperipheral neuropathy, dysarthria, aggression, agitation, confusion,\r\ndepression, hallucinations, restlessness, paraesthesia, lymph node\r\nenlargement, muscle weakness, systemic lupus erythematosus, delayed\r\nmulti-organ hypersensitivity disorder (see also %s\n(From 4.8.1 Control of the epilepsies: British National Formulary)\nAntiepileptic hypersensitivity syndrome\u00a0Antiepileptic hypersensitivity syndrome is a rare but potentially fatal syndrome associated with some antiepileptic drugs (carbamazepine, lacosamide, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, primidone, and rufinamide); rarely cross-sensitivity occurs between some of these antiepileptic drugs. Some other antiepileptics (eslicarbazepine, stiripentol, and zonisamide) have a theoretical risk. The symptoms usually start between 1 and 8 weeks of exposure; fever, rash, and lymphadenopathy are most commonly seen. Other systemic signs include liver dysfunction, haematological, renal, and pulmonary abnormalities, vasculitis, and multi-organ failure. If signs or symptoms of hypersensitivity syndrome occur, the drug should be withdrawn immediately, the patient must not be re-exposed, and expert advice should be sought.); very rarely pancreatitis, stomatitis, hepatic failure, taste\r\ndisturbance, exacerbation of coronary artery disease, AV block with\r\nsyncope, circulatory collapse, hypercholesterolaemia, thrombophlebitis,\r\nthromboembolism, pulmonary hypersensitivity (with dyspnoea, pneumonitis,\r\nor pneumonia), psychosis, neuroleptic malignant syndrome, osteomalacia\r\n(see Cautions), osteoporosis, galactorrhoea, gynaecomastia, impaired\r\nmale fertility, interstitial nephritis, renal failure, sexual dysfunction,\r\nurinary frequency, urinary retention, arthralgia, muscle pain, muscle\r\nspasm, conjunctivitis, angle-closure glaucoma, hearing disorders,\r\nacne, alterations in skin pigmentation, alopecia, hirsutism, sweating,\r\nphotosensitivity, purpura, Stevens-Johnson syndrome, toxic epidermal\r\nnecrolysis, aseptic meningitis; suicidal ideation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/68853.htm", "doses": ["Different preparations may vary in bioavailability;\r\nto avoid reduced effect or excessive side-effects, it may be prudent\r\nto avoid changing the formulation", "Epilepsy, by mouth, initially 100\u2013200\u00a0mg\r\n1\u20132 times daily, increased slowly (see notes above) to usual\r\ndose of 0.8\u20131.2\u00a0g daily in divided doses; in some cases 1.6\u20132\u00a0g daily\r\nin divided doses may be needed; elderly reduce initial dose; child daily\r\nin divided doses, up to 1 year 100\u2013200\u00a0mg, 1\u20135 years 200\u2013400\u00a0mg, 5\u201310\r\nyears 400\u2013600\u00a0mg, 10\u201315 years 0.6\u20131\u00a0g", "By rectum, for short-term use (max. 7 days) when\r\noral therapy temporarily not possible; 125-mg suppository approx.\r\nequivalent to 100-mg tablet, but final adjustment should always depend\r\non clinical response (plasma concentration monitoring recommended);\r\nmax. 1\u00a0g daily in 4 divided doses", "Trigeminal neuralgia, by mouth, initially\r\n100\u00a0mg 1\u20132 times daily (but some patients may require higher initial\r\ndose), increased gradually according to response; usual dose 200\u00a0mg\r\n3\u20134 times daily, up to 1.6\u00a0g daily in some patients", "Prophylaxis of bipolar disorder unresponsive to\r\nlithium (see also section 4.2.3), by mouth, initially 400\u00a0mg\r\ndaily in divided doses increased until symptoms controlled; usual\r\nrange 400\u2013600\u00a0mg daily; max. 1.6\u00a0g daily", "Treatment of alcohol withdrawal [unlicensed indication], by mouth, initially 800\u00a0mg daily in divided doses, reduced\r\ngradually over 5 days to 200\u00a0mg daily; usual treatment duration 7\u201310\r\ndays", "Diabetic neuropathy [unlicensed indication], by mouth, initially 100\u00a0mg 1\u20132 times daily, increased gradually\r\naccording to response; usual dose 200\u00a0mg 3\u20134 times daily, up to 1.6\u00a0g\r\ndaily in some patients", "Plasma concentration for optimum response\r\n4\u201312\u00a0mg/litre (20\u201350\u00a0micromol/litre)"], "pregnancy": "Pregnancy\u00a0see Pregnancy;\r\nmonitor plasma-carbamazepine concentration"}, {"indications": "Indications\u00a0focal and secondary generalised tonic-clonic\r\nseizures, primary generalised tonic-clonic seizures; trigeminal neuralgia;\r\nprophylaxis of bipolar disorder unresponsive to lithium; adjunct in\r\nacute alcohol withdrawal [unlicensed] (section 4.10.1); diabetic neuropathy [unlicensed]\r\n(section 6.1.5)", "name": "CARBAMAZEPINE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.8 Antiepileptic drugs", "4.8.1 Control of the epilepsies", "Carbamazepine and related antiepileptics", "CARBAMAZEPINE", "Modified release"], "cautions": "Cautions\u00a0cardiac disease (see also\r\nContra-indications); skin reactions (see\r\nalso Blood, Hepatic, or Skin Disorders, below and under Side-effects); test for\r\nHLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid\r\nunless no alternative\u2014risk of Stevens-Johnson syndrome in presence\r\nof HLA-B*1502 allele); history of haematological reactions\r\nto other drugs; manufacturer recommends\r\nblood counts and hepatic and renal function tests (but evidence of\r\npractical value uncertain); may exacerbate\r\nabsence and myoclonic seizures; consider\r\nvitamin D supplementation in patients who are immobilised for long\r\nperiods or who have inadequate sun exposure or dietary intake of calcium; susceptibility to angle-closure glaucoma; cross-sensitivity reported with oxcarbazepine and with phenytoin\r\n(see also Antiepileptic Hypersensitivity\r\nSyndrome); avoid abrupt withdrawal; interactions: see Interactions in section 4.8.1 and Appendix 1 (carbamazepine)Blood, hepatic, or skin disorders\u00a0Patients or their carers should be told how to recognise signs of\r\nblood, liver, or skin disorders, and advised to seek immediate medical\r\nattention if symptoms such as fever, rash, mouth ulcers, bruising,\r\nor bleeding develop. Carbamazepine should be withdrawn\r\nimmediately in cases of aggravated liver dysfunction or acute liver\r\ndisease. Leucopenia that is severe, progressive, or associated\r\nwith clinical symptoms requires withdrawal (if necessary under cover\r\nof a suitable alternative).", "side-effects": "Side-effects\u00a0\n(From Carbamazepine and related antiepileptics: British National Formulary)\nCarbamazepine and related antiepileptics; also dry\r\nmouth, nausea, vomiting, oedema, ataxia, dizziness, drowsiness, fatigue,\r\nheadache, hyponatraemia (leading in rare cases to water intoxication),\r\nblood disorders (including eosinophilia, leucopenia, thrombocytopenia,\r\nhaemolytic anaemia, and aplastic anaemia), dermatitis, urticaria; less commonly diarrhoea, constipation, involuntary movements\r\n(including nystagmus), visual disturbances; rarely abdominal pain, anorexia, hepatitis, jaundice, vanishing bile duct\r\nsyndrome, cardiac conduction disorders, hypertension, hypotension,\r\nperipheral neuropathy, dysarthria, aggression, agitation, confusion,\r\ndepression, hallucinations, restlessness, paraesthesia, lymph node\r\nenlargement, muscle weakness, systemic lupus erythematosus, delayed\r\nmulti-organ hypersensitivity disorder (see also %s\n(From 4.8.1 Control of the epilepsies: British National Formulary)\nAntiepileptic hypersensitivity syndrome\u00a0Antiepileptic hypersensitivity syndrome is a rare but potentially fatal syndrome associated with some antiepileptic drugs (carbamazepine, lacosamide, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, primidone, and rufinamide); rarely cross-sensitivity occurs between some of these antiepileptic drugs. Some other antiepileptics (eslicarbazepine, stiripentol, and zonisamide) have a theoretical risk. The symptoms usually start between 1 and 8 weeks of exposure; fever, rash, and lymphadenopathy are most commonly seen. Other systemic signs include liver dysfunction, haematological, renal, and pulmonary abnormalities, vasculitis, and multi-organ failure. If signs or symptoms of hypersensitivity syndrome occur, the drug should be withdrawn immediately, the patient must not be re-exposed, and expert advice should be sought.); very rarely pancreatitis, stomatitis, hepatic failure, taste\r\ndisturbance, exacerbation of coronary artery disease, AV block with\r\nsyncope, circulatory collapse, hypercholesterolaemia, thrombophlebitis,\r\nthromboembolism, pulmonary hypersensitivity (with dyspnoea, pneumonitis,\r\nor pneumonia), psychosis, neuroleptic malignant syndrome, osteomalacia\r\n(see Cautions), osteoporosis, galactorrhoea, gynaecomastia, impaired\r\nmale fertility, interstitial nephritis, renal failure, sexual dysfunction,\r\nurinary frequency, urinary retention, arthralgia, muscle pain, muscle\r\nspasm, conjunctivitis, angle-closure glaucoma, hearing disorders,\r\nacne, alterations in skin pigmentation, alopecia, hirsutism, sweating,\r\nphotosensitivity, purpura, Stevens-Johnson syndrome, toxic epidermal\r\nnecrolysis, aseptic meningitis; suicidal ideation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128414.htm", "doses": ["Different preparations may vary in bioavailability;\r\nto avoid reduced effect or excessive side-effects, it may be prudent\r\nto avoid changing the formulation", "Epilepsy, by mouth, initially 100\u2013200\u00a0mg\r\n1\u20132 times daily, increased slowly (see notes above) to usual\r\ndose of 0.8\u20131.2\u00a0g daily in divided doses; in some cases 1.6\u20132\u00a0g daily\r\nin divided doses may be needed; elderly reduce initial dose; child daily\r\nin divided doses, up to 1 year 100\u2013200\u00a0mg, 1\u20135 years 200\u2013400\u00a0mg, 5\u201310\r\nyears 400\u2013600\u00a0mg, 10\u201315 years 0.6\u20131\u00a0g", "By rectum, for short-term use (max. 7 days) when\r\noral therapy temporarily not possible; 125-mg suppository approx.\r\nequivalent to 100-mg tablet, but final adjustment should always depend\r\non clinical response (plasma concentration monitoring recommended);\r\nmax. 1\u00a0g daily in 4 divided doses", "Trigeminal neuralgia, by mouth, initially\r\n100\u00a0mg 1\u20132 times daily (but some patients may require higher initial\r\ndose), increased gradually according to response; usual dose 200\u00a0mg\r\n3\u20134 times daily, up to 1.6\u00a0g daily in some patients", "Prophylaxis of bipolar disorder unresponsive to\r\nlithium (see also section 4.2.3), by mouth, initially 400\u00a0mg\r\ndaily in divided doses increased until symptoms controlled; usual\r\nrange 400\u2013600\u00a0mg daily; max. 1.6\u00a0g daily", "Treatment of alcohol withdrawal [unlicensed indication], by mouth, initially 800\u00a0mg daily in divided doses, reduced\r\ngradually over 5 days to 200\u00a0mg daily; usual treatment duration 7\u201310\r\ndays", "Diabetic neuropathy [unlicensed indication], by mouth, initially 100\u00a0mg 1\u20132 times daily, increased gradually\r\naccording to response; usual dose 200\u00a0mg 3\u20134 times daily, up to 1.6\u00a0g\r\ndaily in some patients", "Plasma concentration for optimum response\r\n4\u201312\u00a0mg/litre (20\u201350\u00a0micromol/litre)", "Name[Carbagen\u00ae SR  (Generics) ] Tablets, m/r, f/c, scored, carbamazepine\r\n200\u00a0mg, net price 56-tab pack = \u00a35.20; 400\u00a0mg, 56-tab pack = \u00a310.24. \r\n    Label:\r\n    3, 8, 25, counselling, blood, hepatic or skin disorder symptoms (see above), driving (see notes above)Dose\u00a0epilepsy, adult and child over 5 years, as above;\r\ntrigeminal neuralgia, as above; bipolar disorder, as above; total\r\ndaily dose given in 1\u20132 divided doses"], "pregnancy": "Pregnancy\u00a0see Pregnancy;\r\nmonitor plasma-carbamazepine concentration"}]